Antimicrobial resistance (AMR) is becoming a major global public health threat. In this new OHE Research Paper, the authors identify barriers to the development of new products and recommend a hybrid push-pull approach to encouraging innovation.
In December 2010, the UK Department of Health released a consultation document to elicit comments on ‘proposals for a new value-based system of pricing medicines which aims to recognise and reward innovation. The document sets out the principles that would underpin the move to value-based pricing, outlines how the new system could work across the UK and seeks views on a number of key issues’.
Summarised in this post is a just-released OHE Occasional Paper that examines the potentially positive impact of differential pricing in Europe and the overall negative effects of international reference pricing (IRP) measures.
This OHE Seminar Briefing recounts a presentation by Prof Henry Grabowski on US Priority Review Vouchers, intended to provide an incentive for the development of drugs for tropical diseases. One of the originators of the idea, he recounts the history of its development and examines the potential impact of PRVs.
Value-based pricing for new medicines, proposed as part of UK health care reform, would create a QALY-plus approach for drugs approved starting 1 January 2014. For new drugs, this would replace the current PPRS system. The implications for pricing and reimbursement, and innovation, are outlined by Prof Towse in this blog post.
At a recent OHE seminar, Prof Ben Martin (Science and Technology Policy Studies at SPRU, University of Sussex) presented the results of his extensive literature review and qualitative research on how the field of science policy research has evolved and advanced in the 50 years since its inception.
OHE Consulting has released new research on orphan medicinal products (OMPs) in Europe that assesses the effects of the European Union’s 1999 Regulation on Orphan Medicinal Products on the European economy and society.
Legislation in the EU provides incentives for the developmeng of drugs for rare diseases, known as orphan medicinal products (OMPs). At a recent conference, OHE's Dr Mestre-Ferrandiz reported on OHE research that examines the impact of these measures as well as whether and how pricing and reimbursement policies affect access in practice.
Research spillovers exist when research by one organisation creates increased output for other organisations that operate in the same or other sector of the economy. Given current constraints on public, charitable and private research funding, enhancing spillovers may become an important objective in UK science and technology policy. OHE recently collaborated with RAND Europe in a high-level conference that identified priorities for science policy research that can help improve the ability to take advantage of such synergies in the UK.
Antimicrobial resistance to drugs is a growing global public health issue. The EU began a discussion in 2009 about which policies can best encourage the development of new antibiotics. New OHE research uses an economic model to indentify which incentives for innovation are likely to be most successful.